CoChat

SGLT2 Inhibitors in Type 2 Diabetes Mellitus

Ferrannini, Giulia, Savarese, Gianluigi, Cosentino, Francesco · 2022 · Heart Failure Clinics
Cited by 13

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.hfc.2022.03.009

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 48

  1. Von Mrig, 1836, Observations sur les proprietes febrifuges de la phloridzine, Bull Soc Med Gand, 75
  2. von Mering, 1885, Uber kunstlichen diabetes, Centralbl Med Wiss, 23, 531
  3. Chasis, 1933, The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man, J Clin Invest, 12, 1083, 10.1172/JCI100559 · DOI · Paper page
  4. Alvarado, 1962, Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro, Biochim Biophys Acta, 56, 170, 10.1016/0006-3002(62)90543-7 · DOI · Paper page
  5. Vick, 1973, Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs, Am J Physiol, 224, 552, 10.1152/ajplegacy.1973.224.3.552 · DOI
  6. Ehrenkranz, 2005, Phlorizin: a review, Diabetes Metab Res Rev, 21, 31, 10.1002/dmrr.532 · DOI · Paper page
  7. Oku, 1999, T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes, Diabetes, 48, 1794, 10.2337/diabetes.48.9.1794 · DOI · Paper page
  8. Ueta, 2005, Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats, Life Sci, 76, 2655, 10.1016/j.lfs.2004.09.038 · DOI
  9. Ferrannini, 2021, Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility, Diabetes Res Clin Pract, 175, 108796, 10.1016/j.diabres.2021.108796 · DOI
  10. Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 2457, 10.1056/NEJMoa072761 · DOI · Paper page
  11. Hennekens, 2010, Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus, Contemp Clin Trials, 31, 411, 10.1016/j.cct.2010.06.001 · DOI
  12. Savarese, 2019, Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality, Circulation, 139, 1458, 10.1161/CIRCULATIONAHA.118.038339 · DOI
  13. Zannad, 2011, Eplerenone in patients with systolic heart failure and mild symptoms, N Engl J Med, 364, 11, 10.1056/NEJMoa1009492 · DOI · Paper page
  14. 1987, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N Engl J Med, 316, 1429, 10.1056/NEJM198706043162301 · DOI · Paper page
  15. Wiviott, 2019, Dapagliflozin and cardiovascular outcomes in type 2 diabetes, N Engl J Med, 380, 347, 10.1056/NEJMoa1812389 · DOI · Paper page
  16. Furtado, 2019, Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction, Circulation, 139, 2516, 10.1161/CIRCULATIONAHA.119.039996 · DOI · Paper page
  17. Zelniker, 2020, Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58, Eur J Heart Fail
  18. Bajaj, 2020, Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: analysis from the DECLARE-TIMI 58 trial, Diabetes Obes Metab, 22, 1122, 10.1111/dom.14011 · DOI
  19. Kato, 2019, Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus, Circulation, 139, 2528, 10.1161/CIRCULATIONAHA.119.040130 · DOI · Paper page
  20. Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 377, 644, 10.1056/NEJMoa1611925 · DOI · Paper page
  21. Ohkuma, 2020, Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program, Diabetes Obes Metab, 22, 530, 10.1111/dom.13920 · DOI
  22. Bhatt, 2020, Sotagliflozin in patients with diabetes and chronic kidney disease, N Engl J Med, 16
  23. Cavender, 2018, SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL, J Am Coll Cardiol, 71, 2497, 10.1016/j.jacc.2018.01.085 · DOI · Paper page
  24. Ryan, 2018, Diabetes Obes Metab, 20, 2585, 10.1111/dom.13424 · DOI · Paper page
  25. Becher, 2021, Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry, Eur J Heart Fail
  26. Scheen, 2018, Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors, Circ Res, 122, 1439, 10.1161/CIRCRESAHA.117.311588 · DOI · Paper page
  27. Monami, 2018, Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized clinical trials, Diabetes Obes Metab, 20, 1213, 10.1111/dom.13221 · DOI
  28. Cowie, 2020, SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control, Nat Rev Cardiol, 17, 761, 10.1038/s41569-020-0406-8 · DOI · Paper page
  29. Ferrannini, 2018, Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data, Clin Sci (Lond), 132, 2003, 10.1042/CS20171374 · DOI
  30. Ferrannini, 2012, SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects, Nat Rev Endocrinol, 8, 495, 10.1038/nrendo.2011.243 · DOI · Paper page
  31. Ridderstråle, 2014, Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial, Lancet Diabetes Endocrinol, 2, 691, 10.1016/S2213-8587(14)70120-2 · DOI · Paper page
  32. Griffin, 2020, Empagliflozin in heart failure: diuretic and cardiorenal effects, Circulation, 142, 1028, 10.1161/CIRCULATIONAHA.120.045691 · DOI · Paper page
  33. Jensen, 2021, Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial, Lancet Diabetes Endocrinol, 9, 106, 10.1016/S2213-8587(20)30382-X · DOI
  34. Inzucchi, 2015, SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials, Diab Vasc Dis Res, 12, 90, 10.1177/1479164114559852 · DOI · Paper page
  35. Ferrannini, 2016, Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes, Diabetes, 65, 1190, 10.2337/db15-1356 · DOI · Paper page
  36. Lee, 2017, Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts, Free Radic Biol Med, 104, 298, 10.1016/j.freeradbiomed.2017.01.035 · DOI · Paper page
  37. Verma, 2019, Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial, Circulation, 140, 1693, 10.1161/CIRCULATIONAHA.119.042375 · DOI · Paper page
  38. Weber, 2003, Dynamic regulation of sodium/calcium exchange function in human heart failure, Circulation, 108, 2224, 10.1161/01.CIR.0000095274.72486.94 · DOI · Paper page
  39. Yokoyama, 2000, Sarcolemmal Na+/H+ exchanger activity and expression in human ventricular myocardium, J Am Coll Cardiol, 36, 534, 10.1016/S0735-1097(00)00730-0 · DOI
  40. Padan, 2016, Sodium-proton (Na(+)/H(+)) antiporters: properties and roles in health and disease, Met Ions Life Sci, 16, 391
  41. Trum, 2020, Empagliflozin inhibits Na(+)/H(+) exchanger activity in human atrial cardiomyocytes, ESC Heart Fail, 10.1002/ehf2.13024 · DOI
  42. Yurista, 2019, Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction, Eur J Heart Fail, 21, 862, 10.1002/ejhf.1473 · DOI · Paper page
  43. Cappetta, 2020, Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium, Pharmacol Res Jul, 157, 104781, 10.1016/j.phrs.2020.104781 · DOI · Paper page
  44. Fernandes, 2021, Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials, Heart Rhythm, 18, 1098, 10.1016/j.hrthm.2021.03.028 · DOI · Paper page
  45. Liu, 2008, Enhancing mitochondrial Ca2+ uptake in myocytes from failing hearts restores energy supply and demand matching, Circ Res, 103, 279, 10.1161/CIRCRESAHA.108.175919 · DOI · Paper page
  46. Baartscheer, 2017, Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits, Diabetologia, 60, 568, 10.1007/s00125-016-4134-x · DOI · Paper page
  47. Young, 2021, Sotagliflozin, a dual SGLT1/2 inhibitor, improves cardiac outcomes in a normoglycemic mouse model of cardiac pressure overload, Front Physiol, 12, 738594, 10.3389/fphys.2021.738594 · DOI
  48. Pitt, 2021, Does SGLT1 inhibition add benefit to SGLT2 inhibition in type 2 diabetes?, Circulation, 144, 4, 10.1161/CIRCULATIONAHA.121.054442 · DOI

Cited by

See all 13

Metadata

Authors
Ferrannini, G., Savarese, G., & Cosentino, F.
Venue
Heart Failure Clinics
Publisher
Elsevier BV
Published
2022-10
Volume
18
Issue
4
Pages
551-559
ISSN
1551-7136
Cited by
13
References
23
Language
en
Licence
Funders
  • Eli Lilly and Company
  • Novo Nordisk
  • Familjen Erling-Perssons Stiftelse
  • Pfizer
  • Vetenskapsrådet
  • Boston Scientific Corporation
  • AstraZeneca
  • Servier
  • Merck Sharp and Dohme
  • Novartis
  • Cytokinetics
  • Bristol-Myers Squibb
  • Hjärt-Lungfonden
  • Medtronic
  • Boehringer Ingelheim
  • Roche

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.